Pramila Jayapal voices opposition to U.S.-Israel arms sales and criticizes Trump-era actions

U.S. Rep. Pramila Jayapal representing Washington%27s 7th Congressional District - Official U.S. House headshot
U.S. Rep. Pramila Jayapal representing Washington's 7th Congressional District - Official U.S. House headshot
0Comments

U.S. Representative Pramila Jayapal, who has represented Washington’s 7th district in Congress since 2017, posted a series of statements on August 1, 2025, addressing U.S. arms sales to Israel, alleged corporate tax burdens under former President Trump, and concerns about the handling of Epstein-related files.

In a tweet published at 14:43 UTC on August 1, Jayapal stated her support for Senator Bernie Sanders’ efforts to halt offensive weapons sales to Israel. She wrote: “I strongly support @SenSanders’ resolutions to block offensive weapons sales to the Israeli govt — efforts I’ve helped lead in the House. The Israeli govt has repeatedly violated US & int’l law & is starving Gazan civilians. We can’t continue being complicit in their brutal war.”

Later that day at 16:08 UTC, Jayapal criticized financial policies attributed to Donald Trump and corporations, saying: “(That’s $150 billion that Trump and corporations are making YOU pay) https://t.co/5Xyfbiscor”

At 17:25 UTC on August 1, she addressed public concerns over the management of documents related to Jeffrey Epstein by Donald Trump. Jayapal tweeted: “If it looks like a cover-up, sounds like a cover-up, acts like a cover-up… it’s a cover-up. The American people are offended by Trump’s handling of the Epstein files — and they should be. He’s hiding something, and we deserve the truth.”

Pramila Jayapal began serving as Washington’s 7th district representative in Congress after succeeding Jim McDermott in 2017. Prior to her congressional tenure, she was a member of the Washington State Senate from 2014 through 2016. Born in Chennai (formerly Madras State), India in 1965 and currently residing in Seattle at age 57, Jayapal holds degrees from Georgetown University (BA) and Northwestern University.



Related

Dr. Christine S. Lee Acting Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) in the Office of the Commissioner at the U.S. FDA

FDA inspects InnerSea Discoveries – Wilderness Discoverer, LLC in Seattle on July 21, 2024

On July 21, 2024, InnerSea Discoveries – Wilderness Discoverer, LLC in Seattle underwent an FDA inspection focused on food and cosmetics technical assistance, according to information available on the FDA’s website.

Mark Raza Principal Deputy Chief Counsel - FDA

Mark N. Fluchel, M.D. in Seattle scheduled for FDA inspection on Nov. 21, 2024

Mark N. Fluchel, M.D., based in Seattle, underwent an FDA bioresearch monitoring inspection on November 21, 2024, according to information available on the FDA’s website.

James “Jim” Sigg FDA's Deputy Commissioner for Operations and Chief Operating Officer

Kalsada Coffee Company in Seattle inspected by FDA on July 1, 2024

The Food and Drug Administration conducted an inspection of Kalsada Coffee Company in Seattle on July 1, 2024, focusing on foodborne biological hazards, according to FDA website data.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from Seattle City Wire.